Study reveals how neurotransmitters influence brain gene expression
A new study demonstrates how neurotransmitters affect brain gene expression, offering potential therapeutic insights for circadian rhythm disorders.
List view / Grid view
Gene Therapy is the introduction of normal genes into cells in place of missing or defective ones in order to correct genetic disorders.
A new study demonstrates how neurotransmitters affect brain gene expression, offering potential therapeutic insights for circadian rhythm disorders.
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
Viral capsid assembly and quality are key factors in gene therapy success and safety. Here, Dr Chelsea Pratt explores how cutting-edge tools are enabling scientists to tackle these challenges and improve patient outcomes.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
We had the privilege of talking to Veerle d’Haenens, General Manager, Global Therapy Innovations at Terumo Blood and Cell Technologies. Her successful career has been driven by her creativity, expertise and passion, and she advises women who are aspiring to STEM roles to always think big.
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
Tune into this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing…
Fuelled by advances in rare disease treatments and vaccination efforts, Natalia Elizalde, CBO at VIVEbiotech, discusses how the market demand for lentiviral vectors is evolving, the new therapeutic areas emerging as potential targets for in vivo gene therapy and the latest technological advancements in the development and delivery of in…
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
The approach precisely and durably corrects the CFTR mutation in human lung cells, which could lead to superior treatments.